O'Day Daniel Patrick
Chairman & CEO
In the last 12 months, O'Day Daniel Patrick filed 47 SEC Form 4 transactions across 1 issuer: $0 in open-market purchases and $51.2M in open-market sales. 34% of these transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $51.2MOpen-market sells (1y)
- 47Transactions filed
- 1Distinct issuers
- 34%Under Rule 10b5-1
- 2026-10-01Latest filing
Issuers Filed For By open-market buy volume
Recent Form 4 Filings Most recent 47 of 47 (1-year window)
| Date | Ticker | Company | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.8M | 12,000 | $147.7 |
| 2026-10-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $445.9K | 3,000 | $148.6 |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 8,780 | – |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 8,780 | – |
| 2026-09-10 | GILD | GILEAD SCIENCES, INC. | Other | F | $612.5K | 4,230 | $144.8 |
| 2026-09-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $236.0K | 1,600 | $147.5 |
| 2026-09-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.2M | 7,992 | $148.4 |
| 2026-09-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $807.9K | 5,408 | $149.4 |
| 2026-08-03 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $868.7K | 6,700 | $129.7 |
| 2026-08-03 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.0M | 7,700 | $130.8 |
| 2026-08-03 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $78.8K | 600 | $131.3 |
| 2026-07-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.5M | 11,900 | $126.1 |
| 2026-07-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $393.9K | 3,100 | $127.1 |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 8,779 | – |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Exercise | M | $0 | 8,779 | – |
| 2026-06-10 | GILD | GILEAD SCIENCES, INC. | Other | F | $511.8K | 4,213 | $121.5 |
| 2026-06-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.4M | 10,900 | $131.1 |
| 2026-06-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $404.8K | 3,062 | $132.2 |
| 2026-06-01 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $138.0K | 1,038 | $133.0 |
| 2026-04-28 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $895.1K | 6,950 | $128.8 |
| 2026-04-28 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $396.5K | 3,050 | $130.0 |
| 2026-03-27 | GILD | GILEAD SCIENCES, INC. | Sell 10b5-1 | S | $1.4M | 10,000 | $136.8 |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 20,026 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $1.5M | 9,767 | $148.6 |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 20,026 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 32,815 | – |
| 2026-03-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 122,755 | $0.0 |
| 2026-02-27 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 38,396 | $0.0 |
| 2026-02-27 | GILD | GILEAD SCIENCES, INC. | Sell | – | $501.4K | 3,481 | $144.0 |
| 2026-02-27 | GILD | GILEAD SCIENCES, INC. | Sell | – | $931.9K | 6,419 | $145.2 |
| 2026-02-27 | GILD | GILEAD SCIENCES, INC. | Sell | – | $14.6K | 100 | $145.7 |
| 2026-02-05 | GILD | GILEAD SCIENCES, INC. | Grant | – | $7.6M | 115,640 | $66.0 |
| 2026-02-05 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 115,640 | $0.0 |
| 2026-02-05 | GILD | GILEAD SCIENCES, INC. | Sell | – | $17.3M | 115,640 | $150.0 |
| 2026-02-03 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 131,675 | $0.0 |
| 2026-02-03 | GILD | GILEAD SCIENCES, INC. | Grant | – | $10.7M | 74,461 | $143.3 |
| 2026-01-28 | GILD | GILEAD SCIENCES, INC. | Sell | – | $702.2K | 5,032 | $139.5 |
| 2026-01-28 | GILD | GILEAD SCIENCES, INC. | Sell | – | $696.7K | 4,968 | $140.2 |
| 2026-01-23 | GILD | GILEAD SCIENCES, INC. | Grant | – | $7.6M | 115,640 | $66.0 |
| 2026-01-23 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 115,640 | $0.0 |
| 2026-01-23 | GILD | GILEAD SCIENCES, INC. | Sell | – | $15.6M | 115,640 | $135.0 |
| 2025-12-29 | GILD | GILEAD SCIENCES, INC. | Sell | – | $1.2M | 10,000 | $124.8 |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 10,426 | – |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $598.3K | 4,931 | $121.3 |
| 2025-12-10 | GILD | GILEAD SCIENCES, INC. | Grant | – | $0 | 10,426 | – |
| 2025-11-28 | GILD | GILEAD SCIENCES, INC. | Sell | – | $404.4K | 3,212 | $125.9 |
| 2025-11-28 | GILD | GILEAD SCIENCES, INC. | Sell | – | $861.0K | 6,788 | $126.8 |
Methodology & FAQ
How These Filings Are Sourced
All transactions on this page are sourced directly from SEC EDGAR. A complete description of the open-market vs grant distinction, the Rule 10b5-1 plan-reference heuristic, and the per-insider name matching is documented in the Methodology.
What companies does O'Day Daniel Patrick file Form 4 disclosures for?
O'Day Daniel Patrick has filed SEC Form 4 transactions for 1 issuer in the last 12 months: GILEAD SCIENCES, INC. (GILD).
What does the 10b5-1 badge mean on these transactions?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Of O'Day Daniel Patrick's 47 reported transactions in the last 12 months, 16 (34%) reference a 10b5-1 trading plan in the Form 4 footnotes.
Are these all the transactions O'Day Daniel Patrick has executed?
This page shows SEC Form 4 transactions on record in Pactolio's tracked universe for the last 12 months. Form 4 only covers transactions in registered classes of equity at issuers where the person qualifies as an insider (officer, director, or 10% beneficial owner). Trades in funds, foreign issuers, or non-insider positions are not disclosed under Form 4 and are not included here.